1
|
Ben Rejeb S, Beltaifa D, Ghozzi A, Bellil K, Turki S. EpCAM (MOC-31) - immunohistochemical expression in papillary thyroid carcinoma and non invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Tunis Med 2021; 99:1066-1071. [PMID: 35288910 PMCID: PMC8974436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
INTRODUCTION Ep-CAM, is a cell adhesion glycoprotein located on the basolateral cell membrane surface and in the cytoplasm of most normal epithelial cells. It has also been described to be expressed in several malignancies such as lung, digestive, prostate and renal carcinomas suggesting it has a potential role in carcinogenesis. In thyroid carcinoma, Ep-CAM expression has rarely been studied especially in papillary thyroid carcinoma. OBJECTIVE We sought to describe and compare the immunohistochemical expression of MOC31 in papillary thyroid carcinoma and in non invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). METHODS We have retrospectively collected 33 cases of PTC diagnosed in the pathology department of the Security forces hospital during a period of 13 years (2008-2021). We have microscopically reviewed all cases and reclassified 9 of 33 cases as NIFTP. An immunohistochemical automated study have been performed with MOC-31 antibody. The immunostaining was considered positive when it was membranous and/or cytoplasmic. The intensity of staining was scored as weak (score 1), moderate (score 2), and strong (score 3). We have used an immunoscore for assessing level of expression of MOC31 as follows: 0 for <5% of positive cells, 1 for 5-30%, 2 for 31-50%, 3 for 51-70%.The total score resulted by summing the percentage score with the intensity score; the final score was varying from 0 to 7, considered low between 1-4 and high 5-7. RESULTS The mean age of patients was 45,2 years-old for PTC cases and 48,1 years-old for NIFTP cases. A net female predominance was found in both groups (male to female ratio of respectively 0,4 and 0,3). MOC31 expression was found in 19 cases of PTC with a percentage of positive cells varying from 5 to 90%. Percentage of positive cells was variable from 5 to 90%. The immunoscore for positive cells was: 0 in 5/24cases, 1 in 4/24cases, 3 in 9/24cases and 4 in 6/24cases. The intensity of staining was assessed score2 (moderate) in 8 cases and score 3 (high) in 7cases (Figure1-2). Final MOC31 staining score was low in 37,5% (9/24) and high in 62.5% (15/24). Patients with advanced pt2-pt3 stages mostly showed high score of MOC31 staining (61,5%).One case was associated with lymph node involvement and was of a high score. 6 cases showed vascular invasion and was of high MOC31 score. MOC31 was expressed in all NIFTP cases with variable proportion of positive cells (5%-80%). The immunoscore for positive cells was: 0 in 1/9cases, 1 in 2/9cases, 2 in 3/9cases, 3 in 1/9cases and 4 in 2/9cases. The intensity of staining was assessed score 1 (weak) in one case, score 2 (moderate) in 6 cases and score 3 (high) in one case (Figure3-4). The final combined score was low in 66,7 (6/9) and high in 33,3% (3/9). CONCLUSION Our study revealed different immunohistochemical profile of MOC31 in benign and malignant tumors. It has somewhat a diffuse and marked staining in the first group. The changes of MOC31 location as well as its score of staining in PTC and NIFTP could hence be helpful in the differential diagnosis. Our findings also support the potential prognostic value of this molecule that deserves further investigations.
Collapse
Affiliation(s)
- Sarra Ben Rejeb
- Hôpital des Forces de Sécurité Intérieure, Faculté de médecine de Tunis
| | - Dorsaf Beltaifa
- Hôpital des Forces de Sécurité Intérieure, Faculté de médecine de Tunis
| | - Amen Ghozzi
- Hôpital des Forces de Sécurité Intérieure, Faculté de médecine de Tunis
| | - Khadija Bellil
- Hôpital des Forces de Sécurité Intérieure, Faculté de médecine de Tunis
| | - Senda Turki
- Hôpital des Forces de Sécurité Intérieure, Faculté de médecine de Tunis
| |
Collapse
|
2
|
Abstract
Human breast cancer (BC) is one of the leading causes of death for women worldwide, and is characterized by a group of highly heterogeneous lesions. The morphological and biomolecular heterogeneity of BC cells, accompanied by dynamic plasticity of the BC microenvironment and the presence of stem-like cells, make tumor categorization an urgent and demanding task.The major limitations in BC research include the high flexibility rate of breast cancer stem cells (BCSCs) and the difficulty of their identification. Improved profiling methods and extensive characterization of BCSCs were recently presented in BMC Cancer, highlighting that the majority of BC cells had a luminal EpCAMhigh/CD49f+ phenotype, and identification of CD44high/CD24low subpopulation of cancer stem cells significantly improves the flow cytometry measurement of BCSCs with higher stem/progenitor ability.Future developments in single-cell omics will potentially revolutionize cancer biology and clinical practice, providing better understanding of BC heterogeneity, how BCSCs evolve, and which BC cells to target to avoid drug resistance.Please see related research published in BMC Cancer: http://www.biomedcentral.com/1471-2407/13/289/abstract.
Collapse
Affiliation(s)
- Ferdinando Mannello
- Department of Biomolecular Sciences, Section of Clinical Biochemistry and Cell Biology, University Carlo Bo, Via O, Ubaldini 7, Urbino, PU, 61029, Italy.
| |
Collapse
|
3
|
Schlereth B, Kleindienst P, Fichtner I, Lorenczewski G, Brischwein K, Lippold S, da Silva A, Locher M, Kischel R, Lutterbüse R, Kufer P, Baeuerle PA. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3. Cancer Immunol Immunother 2006; 55:785-96. [PMID: 16187083 PMCID: PMC11029878 DOI: 10.1007/s00262-005-0082-x] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2005] [Accepted: 08/10/2005] [Indexed: 11/30/2022]
Abstract
Bispecific single-chain antibody constructs specific for human CD3 have been extensively studied for antitumor activity in human xenograft models using severe combined immunodeficient mice supplemented with human T cells. High efficacy at low effector-to-target ratios, independence of T cell costimuli and a potent activation of previously unstimulated polyclonal T cells were identified as hallmarks of this class of bispecific antibodies. Here we studied a bispecific single-chain antibody construct (referred to as 'bispecific T cell engager', BiTE) in an immunocompetent mouse model. This was possible by the use of a murine CD3-specific BiTE, and a syngeneic melanoma cell line (B16F10) expressing the human Ep-CAM target. The murine CD3-specific BiTE, called 2C11x4-7 prevented in a dose-dependent fashion the outgrowth of subcutaneously growing B16/Ep-CAM tumors with daily i.v. injections of 5 or 50 microg BiTE which was most effective. Treatment with 2C11x4-7 was effective even when it was started 10 days after tumor cell inoculation but delayed treatments showed a reduction in the number of cured animals. 2C11x4-7 was also highly active in a lung tumor colony model. When treatment was started on the day of intravenous tumor cell injection, seven out of eight animals stayed free of lung tumors, and three out of eight animals when treatment was started on day 5. Our study shows that BiTEs also have a high antitumor activity in immunocompetent mice and that there is no obvious need for costimulation of T cells by secondary agents.
Collapse
MESH Headings
- Animals
- Antibodies, Bispecific/immunology
- Antibodies, Bispecific/pharmacokinetics
- Antibodies, Bispecific/therapeutic use
- Antibody Specificity
- Antigens, Neoplasm/immunology
- CD3 Complex/immunology
- Cell Adhesion Molecules/immunology
- Cell Line, Tumor/transplantation
- Dose-Response Relationship, Immunologic
- Drug Screening Assays, Antitumor
- Epithelial Cell Adhesion Molecule
- Humans
- Immunocompetence
- Immunotherapy
- Lung Neoplasms/secondary
- Lung Neoplasms/therapy
- Melanoma, Experimental/immunology
- Melanoma, Experimental/therapy
- Mice
- Mice, Inbred C57BL
- Mice, Inbred NOD
- Mice, SCID
- Neoplasm Transplantation
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/pathology
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/therapy
- Recombinant Fusion Proteins/immunology
- Subcutaneous Tissue
- Xenograft Model Antitumor Assays
Collapse
|
4
|
Mosolits S, Markovic K, Fagerberg J, Frödin JE, Rezvany MR, Kiaii S, Mellstedt H, Jeddi-Tehrani M. T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody. Cancer Immunol Immunother 2005; 54:557-70. [PMID: 15570423 PMCID: PMC11034216 DOI: 10.1007/s00262-004-0620-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2004] [Accepted: 09/12/2004] [Indexed: 10/26/2022]
Abstract
The tumour-associated antigen, Ep-CAM, is over-expressed in colorectal carcinoma (CRC). In the present study, a recombinant Ep-CAM protein or a human anti-idiotypic antibody (anti-Id) mimicking Ep-CAM, either alone or in combination, was used for vaccination of CRC patients (n=9). GM-CSF was given as an adjuvant cytokine. A cellular immune response was assessed by measuring anti-Ep-CAM lymphoproliferation, IFN-gamma production (ELISPOT) and by analysing the TCR BV gene usage within the CD4+ and CD8+ T-cell subsets followed by CDR3 fragment analysis. A proliferative and/or IFN-gamma T-cell response was induced against the Ep-CAM protein in eight out of nine patients, and against Ep-CAM-derived peptides in nine out of nine patients. Analysis of the TCR BV gene usage showed a significantly higher usage of BV12 family in CD4+ T cells of patients both before and after immunisation than in those of healthy control donors (p<0.05). In the CD8+ T-cell subset, a significant (p<0.05) increase in the BV19 usage was noted in patients after immunisation. In individual patients, a number of TCR BV gene families in both CD4+ and CD8+ T cells were over-expressed mainly in post-immunisation samples. Analysis of the CDR3 length polymorphism revealed a higher degree of clonality in post-immunisation samples than in pre-immunisation samples. In vitro stimulation with Ep-CAM protein confirmed the expansion of anti-Ep-CAM T-cell clones. The results indicate that immunisation with the Ep-CAM protein and/or anti-Id entails the induction of an anti-Ep-CAM T-cell response in CRC patients, and suggest that BV19+ CD8+ T cells might be involved in a vaccine-induced immune response.
Collapse
Affiliation(s)
- Szilvia Mosolits
- Immune and Gene Therapy Laboratory, Department of Oncology (Radiumhemmet), Karolinska Institute, Stockholm, Sweden
| | - Katja Markovic
- Immune and Gene Therapy Laboratory, Department of Oncology (Radiumhemmet), Karolinska Institute, Stockholm, Sweden
| | - Jan Fagerberg
- Immune and Gene Therapy Laboratory, Department of Oncology (Radiumhemmet), Karolinska Institute, Stockholm, Sweden
| | - Jan-Erik Frödin
- Immune and Gene Therapy Laboratory, Department of Oncology (Radiumhemmet), Karolinska Institute, Stockholm, Sweden
| | - Mohammad-Reza Rezvany
- Immune and Gene Therapy Laboratory, Department of Oncology (Radiumhemmet), Karolinska Institute, Stockholm, Sweden
| | - Shahryar Kiaii
- Immune and Gene Therapy Laboratory, Department of Oncology (Radiumhemmet), Karolinska Institute, Stockholm, Sweden
| | - Håkan Mellstedt
- Immune and Gene Therapy Laboratory, Department of Oncology (Radiumhemmet), Karolinska Institute, Stockholm, Sweden
- Immune and Gene Therapy Laboratory, Cancer Centre Karolinska, Karolinska Hospital, 171 76 Stockholm, Sweden
| | - Mahmood Jeddi-Tehrani
- Immune and Gene Therapy Laboratory, Department of Oncology (Radiumhemmet), Karolinska Institute, Stockholm, Sweden
- Department of Immunology, Monoclonal Antibody Research Center, Avesina Research Center, Tehran, Iran
| |
Collapse
|
5
|
Songun I, Litvinov SV, van de Velde CJH, Pals ST, Hermans J, van Krieken JHJM. Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer 2005; 92:1767-72. [PMID: 15870832 PMCID: PMC2362035 DOI: 10.1038/sj.bjc.6602519] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2004] [Revised: 02/07/2005] [Accepted: 02/21/2005] [Indexed: 12/03/2022] Open
Abstract
Preoperative staging of gastric cancer is difficult and not optimal. The TNM stage is an important prognostic factor, but it can only be assessed reliably after surgery. Therefore, there is need for additional, reliable prognostic factors that can be determined preoperatively in order to select patients who might benefit from (neo) adjuvant treatment. Expression of immunohistochemical markers was demonstrated to be associated with tumour progression and metastasis. The expression of p53, CD44 (splice variants v5, v6 and v9), E-cadherin, Ep-CAM (CO17-1A antigen) and c-erB2/neu were investigated in tumour tissues of 300 patients from the Dutch Gastric Cancer Trial, investigating the value of extended lymphadenectomy compared to that of limited lymphadenectomy). The expression of tumour markers was analysed with respect to patient survival. Patients without loss of Ep-CAM-expression of tumour cells (19%) had a significantly better 10-year survival (P<0.0001) compared to patients with any loss: 42% (s.e.=7%) vs 22% (s.e.=3%). Patients with CD44v6 (VFF18) expression in more than 25% of the tumour cells (69% of the patients) also had a significantly better survival (P=0.01) compared to patients with expression in less than 25% of the tumour cells: 10 year survival rate of 29% (s.e.=3%) vs 19% (s.e.=4%). The prognostic value of both markers was stronger in stages I and II, and independent of the TNM stage. Ep-CAM and CD44v6-expression provides prognostic information additional to the TNM stage. Loss of Ep-CAM-expression identifies aggressive tumours especially in patients with stage I and II disease. This information may be helpful in selecting patients suitable for surgery or for additional treatment pre- or postoperatively.
Collapse
Affiliation(s)
- I Songun
- Department of Surgery, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
| | - S V Litvinov
- Department of Pathology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
| | - C J H van de Velde
- Department of Surgery, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
| | - S T Pals
- Department of Pathology, Academic Medical Center, PO Box 22660, 1100 DD Amsterdam, The Netherlands
| | - J Hermans
- Department of Medical Statistics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
| | - J H J M van Krieken
- Department of Pathology, Radbond University, Nijmegen Medical Center, PO Box 9101, 6500 HB Nijimegen, The Netherlands
| |
Collapse
|
6
|
Thurmond LM, Stimmel JB, Ingram AC, Ryan CH, Murray DM, Eberwein DJ, Witherspoon SM, Knick VC. Adenocarcinoma cells exposed in vitro to Navelbine or Taxol increase Ep-CAM expression through a novel mechanism. Cancer Immunol Immunother 2003; 52:429-37. [PMID: 12695858 PMCID: PMC11034270 DOI: 10.1007/s00262-003-0386-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2002] [Accepted: 01/28/2003] [Indexed: 12/01/2022]
Abstract
Ep-CAM antigen expression was shown to vary by phase across the cell cycle. Following pretreatment of various adenocarcinoma cells in culture with clinically relevant concentrations of vinorelbine tartrate (Navelbine) or paclitaxel (Taxol), cell surface expression of Ep-CAM antigen increased by two- to ten-fold compared to that of untreated control cells and was associated with arrest of cell cycle progression and accumulation of cells in the S and G2/M phases. We demonstrated that increases in cell surface antigen expression resulted in improved biological effectiveness of the targeting antibody as measured in vitro by antibody-dependent cellular cytotoxicity and in vivo by enhanced antibody targeting to Ep-CAM-expressing xenografts in mice pretreated with Navelbine. No effect on cell cycle progression or Ep-CAM antigen expression was seen with human interferon-alpha and interferon-gamma, agents that increase gene expression of various tumor and normal antigens and may upregulate some antigens. Thus, the upregulation of cell surface Ep-CAM expression following pretreatment with G2/M blockers is through a novel mechanism involving residence time of the antigen on the cell surface. This significant increase in Ep-CAM expression appears to be tumor-specific since we saw no increase in antigen expression on normal epithelial cells. Studies to reveal relative internalization rates suggest that the increase in cell surface expression of Ep-CAM following pretreatment with G2/M blockers is a consequence of an inhibition of normal cycles of antigen endocytosis and expression on the cell surface. The present work provides a mechanism for the improved clinical efficacy of therapeutic antibodies used in combination with traditional cell cycle-specific chemotherapeutic drugs.
Collapse
Affiliation(s)
- Linda M. Thurmond
- />Department of Translational Medicine and Technology, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709 USA
| | - Julie B. Stimmel
- />Department of Systems Research, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709 USA
| | - Adrienne C. Ingram
- />Parexel, Inc., 12300 Twinbrook Pkwy, Suite 315, Rockville, MD 20852 USA
| | - Christian H. Ryan
- />Amgen Inc, 4000 Nelson Road, Mailstop AC-22D, Longmont, CO 80503 USA
| | - Doris M. Murray
- />Department of Cancer Biology, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709 USA
| | - Derek J. Eberwein
- />Department of Cancer Biology, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709 USA
| | - Sam M. Witherspoon
- />Department of High Throughput Biology, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709 USA
| | - Vincent C. Knick
- />Department of Information Analysis, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709 USA
| |
Collapse
|
7
|
Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M, Fong D, Amberger A, Margreiter R, Obrist P. Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 2003; 88:574-8. [PMID: 12592372 PMCID: PMC2377167 DOI: 10.1038/sj.bjc.6600741] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Recent studies have demonstrated cyclooxygenase 2 (COX-2) overexpression in various human malignancies, especially in breast cancer, where COX-2 turned out to be a predictor of poor survival. To evaluate the relation of COX-2 and Ep-CAM overexpression and its prognostic significance, we performed a retrospective study on 212 breast cancer patients with a median follow-up time of 10.5 years. Overexpression of COX-2 in tumour tissue samples was assessed by immunohistochemistry. COX-2 overexpression was found in 48.6% of the tumour samples and was predictive for poor disease-free and overall survival. Univariate analysis revealed a strong correlation between COX-2 and Ep-CAM overexpression (P=0.009). Concurrent COX-2 and Ep-CAM overexpression was present in 21.7% of tumour specimens and had an additive negative impact on disease-free and overall survival. Determination of both tumour markers should help in guiding new therapeutic strategies in patients with invasive breast cancer.
Collapse
Affiliation(s)
- G Spizzo
- Division of Haematology & Oncology, University of Innsbruck, A-6020 Innsbruck, Austria
| | - G Gastl
- Division of Haematology & Oncology, University of Innsbruck, A-6020 Innsbruck, Austria
| | - D Wolf
- Division of Haematology & Oncology, University of Innsbruck, A-6020 Innsbruck, Austria
| | - E Gunsilius
- Division of Haematology & Oncology, University of Innsbruck, A-6020 Innsbruck, Austria
| | - M Steurer
- Division of Haematology & Oncology, University of Innsbruck, A-6020 Innsbruck, Austria
| | - D Fong
- Department of Pathology, University of Innsbruck, A-6020 Innsbruck, Austria
| | - A Amberger
- Tyrolean Cancer Research Institute, University of Innsbruck, A-6020 Innsbruck, Austria
| | - R Margreiter
- Tyrolean Cancer Research Institute, University of Innsbruck, A-6020 Innsbruck, Austria
| | - P Obrist
- Department of Pathology, University of Innsbruck, A-6020 Innsbruck, Austria
- Department of Pathology, Innsbruck University Hospital, Müllerstrasse, 44, A-6020 Innsbruck, Austria. E-mail:
| |
Collapse
|
8
|
Huls G, Gestel D, van der Linden J, Moret E, Logtenberg T. Tumor cell killing by in vitro affinity-matured recombinant human monoclonal antibodies. Cancer Immunol Immunother 2001; 50:163-71. [PMID: 11419184 PMCID: PMC11036830 DOI: 10.1007/s002620100182] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
We have developed a method that allows the rapid improvement of the affinity of phage-displayed antibody fragments by selection on intact eukaryotic cells. A single chain Fv fragment, specific for the tumor-associated Ep-Cam molecule, was mutagenized by shuffling of the immunoglobulin light chain variable region and DNA shuffling of both heavy and light chain variable regions. Higher-affinity mutants were selected from small phage display libraries by cell panning under stringent conditions. When converted to an intact fully human antibody, the mutagenized anti-tumor monoclonal antibody displayed an affinity of 0.4 nM, a 15-fold improvement over the affinity of the original antibody. Compared to previously reported affinity maturation schemes, panning on intact cells does not require purified targets for selection and may be particularly useful when the target molecule can not be expressed as a recombinant molecule or easily purified without disrupting its native configuration. In vitro tumor cell killing assays demonstrated an improved performance of the higher-affinity antibody in complement-mediated tumor cell killing. In contrast, the lower-affinity antibody performed somewhat better in antibody-dependent cellular cytotoxicity assays and penetrated better in multicell spheroids of tumor cells, an in vitro model for the tumor penetration capacity of antibodies.
Collapse
Affiliation(s)
- Gerwin Huls
- />Crucell and Department of Immunology HP F.03.821, University Hospital Utrecht, Heidelberglaan 100, 3508 GA Utrecht, The Netherlands e-mail: Tel.: +31-30-2507674; Fax: +31-30-2517107, , , , NL
| | - David Gestel
- />Department of Medicinal Chemistry, Utrecht University, Utrecht, The Netherlands, , , , NL
| | - Joke van der Linden
- />Crucell and Department of Immunology HP F.03.821, University Hospital Utrecht, Heidelberglaan 100, 3508 GA Utrecht, The Netherlands e-mail: Tel.: +31-30-2507674; Fax: +31-30-2517107, , , , NL
| | - Ed Moret
- />Department of Medicinal Chemistry, Utrecht University, Utrecht, The Netherlands, , , , NL
| | - Ton Logtenberg
- />Crucell and Department of Immunology HP F.03.821, University Hospital Utrecht, Heidelberglaan 100, 3508 GA Utrecht, The Netherlands e-mail: Tel.: +31-30-2507674; Fax: +31-30-2517107, , , , NL
| |
Collapse
|